Form 4: Alnylam Pharmaceuticals Director Exercises Stock Options

Amy Schulman, a director at Alnylam Pharmaceuticals, exercised stock options to acquire 2,750 shares of common stock at a price of $131.21 on March 13, 2025.

Summary

• On March 13, 2025, Amy Schulman, a director of Alnylam Pharmaceuticals, exercised stock options.
• This transaction involved the acquisition of 2,750 shares of Alnylam's common stock.
• The exercise price for the stock options was $131.21 per share.
• Following the transaction, Schulman directly owns 11,186 shares of Alnylam common stock.
• The stock options exercised were fully vested as of June 1, 2016, and were due to expire on June 1, 2025.

Sentiment

Score: 5

Explanation: This is a neutral event, reflecting a standard transaction of a director exercising stock options. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This is a routine disclosure of a director exercising vested stock options, which is a common practice in publicly traded companies. It reflects the director's investment in the company's stock.

Comparison to Industry Standards

• Director stock option exercises are a common occurrence in publicly traded companies, particularly in the pharmaceutical industry.
• The vesting and expiration terms of the options are typical for executive compensation packages.
• Similar transactions are regularly reported by directors and officers of companies like Moderna, BioNTech, and Gilead Sciences.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it represents a small percentage of the total outstanding shares.
• The exercise of options by a director can be seen as a positive signal, indicating confidence in the company's future performance.

Key Dates